Q-omics provides the consensus-scored IMPDH1P3 profile across patient tissues and cancer cell-line models. IMPDH1P3 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, IMPDH1P3 is differentially expressed in 4, with the highest sampling consensus in HNSC. Additionally, IMPDH1P3 RNA expression shows 6,175 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight DLBC, HNSC, and STAD as cancer lineages where IMPDH1P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IMPDH1P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IMPDH1P3 survival associations across molecular data types. IMPDH1P3 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IMPDH1P3 RNA expression–survival associations across cancer types. High IMPDH1P3 expression shows unfavorable associations in DLBC, STAD, LIHC and LUSC, but favorable associations in ESCA and BRCA. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify DLBC as the clearest survival context for IMPDH1P3 RNA expression.
This table summarizes IMPDH1P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for IMPDH1P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IMPDH1P3 shows higher tumor expression in HNSC, COAD, LUSC and LUAD. The HNSC box plot shows higher IMPDH1P3 RNA expression in tumor versus normal tissue (log2 FC = +0.054, t-test p < 0.001).
This table shows molecular features associated with IMPDH1P3 in patient tissues and cancer cell lines. In patient samples, IMPDH1P3 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
